Clinical Trials Browser

Phase 2 × Thyroid Neoplasms × tislelizumab × Clear all

NCT05659186 2022-12-21

PD-1 Inhibitor and Anlotinib Combined With Multimodal Radiotherapy in Recurrent or Metastatic Anaplastic Thyroid Cancer

Phase 2 Unknown

Thyroid Neoplasms